Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Explores AI Content Marketplace With Media Publishers 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SAN FRANCISCO, Jan. 31, 2018 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the fourth quarter 2017 after the close of trading on Wednesday, February 14, 2018. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, using Conference ID: 4859609. A live and archived webcast of the event will be available on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact:
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
Media Contact
Aaron Murphy
(415) 229-3331
[email protected]
